Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$6.85 USD

6.85
107,617

-0.34 (-4.73%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $6.85 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

KMDA or ACAD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

KMDA vs. ACAD: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Kamada (KMDA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength?

by Zacks Equity Research

Kamada (KMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

KMDA vs. ACAD: Which Stock Is the Better Value Option?

by Zacks Equity Research

KMDA vs. ACAD: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy Kamada (KMDA) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Implied Volatility Surging for Kamada Stock Options

by Zacks Equity Research

Investors need to pay close attention to Kamada stock based on the movements in the options market lately.

Zacks Equity Research

Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 106.9% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Are Investors Undervaluing Kamada (KMDA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

KMDA vs. CSLLY: Which Stock Is the Better Value Option?

Zacks Equity Research

Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Kamada (KMDA) points to a 106.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Is Kamada (KMDA) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Kamada (KMDA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Kamada (KMDA) Q1 Earnings Match Estimates

by Zacks Equity Research

Kamada (KMDA) delivered earnings and revenue surprises of 0% and 5.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

XOMA Royalty (XOMA) delivered earnings and revenue surprises of 123.08% and 159.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Kamada (KMDA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Zacks Equity Research

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 400% and 4.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0% and 23.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Keros Therapeutics (KROS) delivered earnings and revenue surprises of 36,300% and 149.64%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why

by Zacks Equity Research

Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.

Zacks Equity Research

Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.

Zacks Equity Research

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

by Zacks Equity Research

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.

Zacks Equity Research

Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer

by Zacks Equity Research

Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.

Zacks Equity Research

Pfizer's (PFE) Etrasimod Filings Receive Review Acceptance

by Zacks Equity Research

The regulatory filings seek approval for Pfizer's (PFE) etrasimod in UC indication. A final decision in the U.S. is expected in 2023, while the decision in the EU is expected in 2024.

Zacks Equity Research

Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug

by Zacks Equity Research

Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.